A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations.
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Mar 2018
At a glance
- Drugs Erdafitinib (Primary) ; Docetaxel; Pembrolizumab; Vinflunine
- Indications Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms THOR
- Sponsors Janssen-Cilag
- 11 Mar 2018 Planned number of patients changed from 630 to 631.
- 11 Mar 2018 Planned End Date changed from 27 Aug 2021 to 27 May 2021.
- 06 Mar 2018 New trial record